series-b
Stage
1
Investors
About
Normunity develops biologic anti-cancer therapies targeting tumor-specific, immune-active cell surface proteins to overcome tumor growth and immune evasion, with a lead T cell engager program in clinical trials.
Explore Normunity's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.